BioCentury
ARTICLE | Clinical News

RGSH4K: Phase I started

November 16, 2015 8:00 AM UTC

Regeneus began the open-label, dose-escalation, Australian Phase I ACTIVATE trial to evaluate intradermal RGSH4K using 100, 250 or 500 ug streptavidin on weeks 1, 4 and 7 in up to 21 patients. ...